Document is current
Any future updates will be listed below
-
Authors
Soudant, Juliette
Lejeune, Stéphanie
Aumar, Madeleine
Caron, Nicolas
Lengline, Hélène
Hoarau, Cyrille
Kalach, Nicolas
Enaud, Raphaël
Bonneton, Marjorie
Dupont-Lucas, Claire
Fabre, Alexandre
Butori, Mathilde
Lemoine, Anaïs
Bridoux-Henno, Laure
Rebeuh, Julie
Dimitrov, Georges
Caillau, Émeline
Gottrand, Frédéric
Tran, Léa Chantal https://orcid.org/0000-0002-7574-7956
- License Information
-
More Information
Article History
Received: 4 December 2024
Revised: 12 February 2025
Accepted: 20 February 2025
First Online: 7 June 2025
Competing interests
: Nicolas Caron: Consultant fees from Sanofi. Claire Dupont-Lucas: Consultant fees from Sanofi. Frederic Gottrand: Member of advisory board – Sanofi. Nicolas Kalach: Member of advisory board - Dr Falk and Sanofi. Stéphanie Lejeune: honoraria for communications (SANOFI), honoraria for training activities (SANOFI – NOVARTIS – STALLERGENES), funding for participation at conferences and congresses (SANOFI, ALK, GSK), research grant mobility (ASTRA ZENECA). Anaïs Lemoine: Grünenthal. The other authors have no conflict of interest to declare.
: Non opposition form was obtained from all patients or their parents or legal guardians prior to enrollment by the doctor treating the patient or one of the investigators.
